ERBB2 and breast carcinoma: Consistent with the increased frequency of p53 mutations in HER2 and TNBC subtypes [37], and our profiling of Toca-1 in breast cancer cell lines [11], we observed significantly increased Toca-1 expression levels in these subtypes compared to luminal tumors (Figure 6C,D).